Search Results - "Gordoa, Teresa Alonso"

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study by Choueiri, Toni K, Eto, Masatoshi, Motzer, Robert, De Giorgi, Ugo, Buchler, Tomas, Basappa, Naveen S, Méndez-Vidal, María José, Tjulandin, Sergei, Hoon Park, Se, Melichar, Bohuslav, Hutson, Thomas, Alemany, Carlos, McGregor, Bradley, Powles, Thomas, Grünwald, Viktor, Alekseev, Boris, Rha, Sun Young, Kopyltsov, Evgeny, Kapoor, Anil, Alonso Gordoa, Teresa, Goh, Jeffrey C, Staehler, Michael, Merchan, Jaime R, Xie, Ran, Perini, Rodolfo F, Mody, Kalgi, McKenzie, Jodi, Porta, Camillo G

“…In the primary analysis of the CLEAR study, lenvatinib plus pembrolizumab significantly improved progression-free survival and overall survival versus…”
Get full text

Multimodal approach to the treatment of patients with radioiodine refractory differentiated thyroid cancer and metastases to the central nervous system by Alonso‐Gordoa, Teresa

“…The diagnosis of central nervous system metastases in patients with radioiodine refractory differentiated thyroid cancer is a late and rare event that occurs…”
Get full text

Tumor‐associated macrophages: “Good cop‐bad cop” by Molina‐Cerrillo, Javier, Alonso‐Gordoa, Teresa, Garrido, Pilar

Get full text

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma by Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E., Kopyltsov, Evgeny, Méndez-Vidal, María J., Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R., Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C., Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E., Smith, Alan D., Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F., Xing, Dongyuan, Choueiri, Toni K.

Get full text

The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE‐1407) by Grande, Enrique, Teulé, Alex, Alonso‐Gordoa, Teresa, Jiménez‐Fonseca, Paula, Benavent, Marta, Capdevila, Jaume, Custodio, Ana, Vera, Ruth, Munarriz, Javier, La Casta, Adelaida, Díez, Juan José, Gajate, Pablo, Molina‐Cerrillo, Javier, Matos, Ignacio, Cristóbal, Eva María, Ruffinelli, José C., Palacios, José, García‐Carbonero, Rocío

“…Lessons Learned Palbociclib demonstrated no detectable activity in molecularly unselected and heavily pretreated patients with advanced grade 1/2 pancreatic…”
Get full text

A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide by Fernandez‐Perez, María P., Perez‐Navarro, Enrique, Alonso‐Gordoa, Teresa, Conteduca, Vicenza, Font, Albert, Vázquez‐Estévez, Sergio, González‐del‐Alba, Aránzazu, Wetterskog, Daniel, Antonarakis, Emmanuel S., Mellado, Begona, Fernandez‐Calvo, Ovidio, Méndez‐Vidal, María J., Climent, Miguel A., Duran, Ignacio, Gallardo, Enrique, Rodriguez Sanchez, Angel, Santander, Carmen, Sáez, Maria I., Puente, Javier, Tudela, Julian, Martínez, Alberto, López‐Andreo, Maria J., Padilla, José, Lozano, Rebeca, Hervas, David, Luo, Jun, Giorgi, Ugo, Castellano, Daniel, Attard, Gerhardt, Grande, Enrique, Gonzalez‐Billalabeitia, Enrique

“…Background There is a considerable need to incorporate biomarkers of resistance to new antiandrogen agents in the management of castration‐resistant prostate…”
Get full text

Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours by Dawod, Mohammed, Gordoa, Teresa Alonso, Cives, Mauro, De Mestier, Louis, Crona, Joakim, Spada, Francesca, Oberg, Kjel, Pavel, Marianne, Lamarca, Angela

“…Opinion statement Neuroendocrine neoplasms (NENs) are a heterogeneous group of malignancies with rising incidence and prevalence. Outcome and therapy of small…”
Get full text

The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide by Serrano Domingo, Juan José, Alonso Gordoa, Teresa, Lorca Álvaro, Javier, Molina-Cerrillo, Javier, Barquín García, Arantzazu, Martínez Sáez, Olga, Burgos Revilla, Javier, Carrato, Alfredo, Álvarez Rodríguez, Sara

“…Introduction: Androgenic deprivation therapies have been linked to the development of metabolic syndrome (MS) and cardiovascular diseases, which may lead to a…”
Get full text

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma by Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K

“…Lenvatinib plus either pembrolizumab or everolimus was compared with sunitinib as first-line therapy for advanced renal cell cancer. Progression-free survival…”
Get full text

Inhibition of Serotonin Synthesis May Have Antitumor Activity? Long‐Term Efficacy in a Patient with Gastrointestinal Neuroendocrine Tumor by Molina‐Cerrillo, Javier, Grande, Enrique, Alonso‐Gordoa, Teresa

“…In this article, we propose, based on a clinical case, the potential antitumor effect related to the inhibition of serotonin in neuroendocrine tumors (NETs)…”
Get full text

Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys" by Alonso-Gordoa, Teresa, García-Bermejo, María Laura, Grande, Enrique, Garrido, Pilar, Carrato, Alfredo, Molina-Cerrillo, Javier

“…Clear cell renal cell carcinoma (ccRCC) is the seventh most frequently diagnosed tumor in adults in Europe and represents approximately 2.5% of cancer deaths…”
Get full text

Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki‐67 Is ≥10%? by Merola, Elettra, Alonso Gordoa, Teresa, Zhang, Panpan, Al‐Toubah, Taymeyah, Pellè, Eleonora, Kolasińska‐Ćwikła, Agnieszka, Zandee, Wouter, Laskaratos, Faidon, Mestier, Louis, Lamarca, Angela, Hernando, Jorge, Cwikla, Jaroslaw, Strosberg, Jonathan, Herder, Wouter, Caplin, Martin, Cives, Mauro, Leeuwaarde, Rachel

“…Background Long‐acting somatostatin analogs (SSAs) are the primary first‐line treatment of well‐differentiated advanced gastroenteropancreatic neuroendocrine…”
Get full text

Tyrosine Kinase Receptors in Oncology by Esteban-Villarrubia, Jorge, Soto-Castillo, Juan José, Pozas, Javier, San Román-Gil, María, Orejana-Martín, Inmaculada, Torres-Jiménez, Javier, Carrato, Alfredo, Alonso-Gordoa, Teresa, Molina-Cerrillo, Javier

“…Tyrosine kinase receptors (TKR) comprise more than 60 molecules that play an essential role in the molecular pathways, leading to cell survival and…”
Get full text

Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma by Loriot, Yohann, Sternberg, Cora N., Castellano, Daniel, Oosting, Sjoukje F., Dumez, Herlinde, Huddart, Robert, Vianna, Karina, Alonso Gordoa, Teresa, Skoneczna, Iwona, Fay, Andre P., Nolè, Franco, Massari, Francesco, Brasiuniene, Birute, Maroto, Pablo, Fear, Simon, Di Nucci, Flavia, de Ducla, Sabine, Choy, Ernest

“…Patients with pre-existing autoimmune disease (AID) are typically excluded from clinical trials of immune checkpoint inhibitors, and there are limited data on…”
Get full text

Sunitinib and Evofosfamide (TH‐302) in Systemic Treatment‐Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE‐1408 Trial by Grande, Enrique, Rodriguez‐Antona, Cristina, López, Carlos, Alonso‐Gordoa, Teresa, Benavent, Marta, Capdevila, Jaume, Teulé, Alex, Custodio, Ana, Sevilla, Isabel, Hernando, Jorge, Gajate, Pablo, Molina‐Cerrillo, Javier, Díez, Juan José, Santos, María, Lanillos, Javier, García‐Carbonero, Rocío

“…Background Sunitinib (SUN)‐induced hypoxia within the tumor could promote the activation of the prodrug evofosfamide (EVO), locally releasing the cytotoxic DNA…”
Get full text

Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer by Gómez de Liaño Lista, Alfonso, van Dijk, Nick, de Velasco Oria de Rueda, Guillermo, Necchi, Andrea, Lavaud, Pernelle, Morales-Barrera, Rafael, Alonso Gordoa, Teresa, Maroto, Pablo, Ravaud, Alain, Durán, Ignacio, Szabados, Bernadett, Castellano, Daniel, Giannatempo, Patrizia, Loriot, Yohann, Carles, Joan, Anguera Palacios, Georgia, Lefort, Felix, Raggi, Daniele, Gross Goupil, Marine, Powles, Thomas, Van der Heijden, Michiel S.

“…Immune checkpoint inhibitors (ICIs) are approved for first-line (cisplatin unfit, PD-L1+) and platinum-refractory urothelial carcinoma (UC). Still, most…”
Get full text

Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial by Rha, Sun Young, Choueiri, Toni K., Matveev, Vsevolod B., Alyasova, Anna, Hong, Sung‐Hoo, Gordoa, Teresa Alonso, Gurney, Howard, Bjarnason, Georg A., Buchler, Tomas, Pedrazzoli, Paolo, Takagi, Toshio, Park, Se Hoon, Lee, Jae Lyun, Perini, Rodolfo F., He, Cixin S., McKenzie, Jodi A., Eto, Masatoshi

“…In the CLEAR trial, lenvatinib plus pembrolizumab met study endpoints of superiority vs sunitinib in the first‐line treatment of patients with advanced renal…”
Get full text

Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study) by Solis-Hernandez, Mª Pilar, Fernandez del Valle, Ana, Carmona-Bayonas, Alberto, Garcia-Carbonero, Rocio, Custodio, Ana, Benavent, Marta, Alonso Gordoa, Teresa, Nuñez-Valdovino, Bárbara, Sanchez Canovas, Manuel, Matos, Ignacio, Alonso, Vicente, Lopez, Carlos, Viudez, Antonio, Izquierdo, Marta, Calvo-Temprano, David, Grande, Enrique, Capdevila, Jaume, Jimenez-Fonseca, Paula

“…Background The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs)…”
Get full text

Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913) by Riesco-Martinez, Maria Carmen, Capdevila, Jaume, Alonso, Vicente, Jimenez-Fonseca, Paula, Teule, Alex, Grande, Enrique, Sevilla, Isabel, Benavent, Marta, Alonso-Gordoa, Teresa, Custodio, Ana, Anton-Pascual, Beatriz, Hernando, Jorge, Polo, Eduardo, Castillo-Trujillo, Oscar Alfredo, Lamas-Paz, Arantza, Teijo, Ana, Rodriguez-Gil, Yolanda, Soldevilla, Beatriz, Garcia-Carbonero, Rocio

“…The prognosis of patients with advanced high-grade (G3) digestive neuroendocrine neoplasms (NENs) is rather poor. The addition of immune checkpoint inhibition…”
Get full text

Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms by Pozas, Javier, San Román, María, Alonso-Gordoa, Teresa, Pozas, Miguel, Caracuel, Laura, Carrato, Alfredo, Molina-Cerrillo, Javier

“…Despite being infrequent tumors, the incidence and prevalence of pancreatic neuroendocrine tumors (P-NETs) has been rising over the past few decades. In recent…”
Get full text